➤ Fatigue, sleep disturbances, and depressive symptoms are signifi cantly higher in women with stage II breast cancer receiving adjuvant chemotherapy compared to disease-free women.
B
reast cancer frequently requires adjuvant chemotherapy to treat micrometatastic disease following surgery. Although clinical trials have demonstrated long diseasefree intervals with curative intent, the treatment frequently involves signifi cant short-and long-term side effects, including fatigue, sleep disturbances, and depressive symptoms. Fatigue continues to be described as the most common and distressing symptom associated with chemotherapy (Irvine, Vincent, Graydon, Bubela, & Thompson, 1994; Jacobsen et al., 1999; Mock, 2004; Payne, 2002; Piper, Lindsey, & Dodd, 1987; Winningham et al., 1994) , but little is known about the underlying etiology of fatigue and its closely interrelated association with sleep disturbances and depressive symptoms or its association with select biomarkers (i.e., serum cortisol, melatonin, serotonin, and bilirubin). The frequency and prevalence of this symptom cluster and related sequelae identify it as a signifi cant problem for patients with cancer receiving treatment.
The neuroendocrine system, specifi cally the hypothalamicpituitary-adrenal (HPA) axis, provides regulatory functions; the changes in the production of biochemical levels produced in the axis likely exert complex interactions and infl uences that researchers are only beginning to understand (Cleeland et al., 2003; Payne, 2004; Vgontzas & Chrousos, 2002 Purpose/Objectives: To evaluate the changes in reports of fatigue, sleep disturbances, and depressive symptoms and serum cortisol, melatonin, serotonin, and bilirubin during adjuvant chemotherapy in women with breast cancer and to determine whether any correlations exist between the symptom parameters and biomarkers.
Design: Prospective longitudinal, correlational, repeated-measures pilot study.
Setting: Large southwestern, university-based, National Cancer Institute-designated cancer center.
Sample: 22 subjects (11 women with stage II breast cancer receiving adjuvant chemotherapy and 11 cancer-free women who were matched by age, ethnicity, and menopausal status).
Methods: Questionnaires (fatigue, sleep, depressive symptoms), wrist sleep actigraphy, and laboratory analysis of serum samples. All subjects (i.e., women with breast cancer receiving chemotherapy and a comparison group of cancer-free women who were matched by age, ethnicity, and menopausal status) were admitted to a general clinical research center for two nights during cycles 1 and 4 for data collection.
Main Research Variables: Biomarkers (serum cortisol, melatonin, serotonin, and bilirubin), fatigue, sleep, and depressive symptoms.
Findings: Mean fatigue scores of the subjects with cancer were signifi cantly higher than the healthy comparison group. Subjects with cancer had a signifi cantly lower mean actual sleep time compared to the comparison group at cycle 1. No signifi cant difference was found between the groups at cycle 4. Depression scores also differed signifi cantly between the cancer group and comparison group. Select biomarkers changed over time and were associated with subjective parameters of fatigue, sleep, and depressive symptoms.
Conclusions: Findings suggest that fatigue, sleep, and depressive symptoms are more prevalent in women with cancer than a cancer-free comparison group. Biomarkers changed over time and provide a possible explanatory mechanism for the three related symptoms.
Implications for Nursing: Data help to explain a mechanism that may underlie fatigue, sleep, and depressive symptoms and provide a theoretical framework from which to establish evidence-based interventions for symptom management. This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org.
